Latest News and Press Releases

Dr. Sergey Motov at Maimonides Medical Center to Host Webinar on using MeMed BV® in the Emergency Department to rapidly differentiate bacterial and viral infections HAIFA, Israel, 13 July, 2022 –...

Maccabi Healthcare Services announces it is the first HMO in the world to include MeMed BV® test as part of routine care Groundbreaking host-response test distinguishes between bacterial and viral...

MeMed to Participate in Upcoming Conferences HAIFA, Israel, April 29, 2022 – MeMed (or “the Company”), a leader in the emerging field of advanced host-response technologies, today announces that it...

HAIFA, Israel, April 21, 2022 – MeMed (or “the Company”), a leader in the emerging field of advanced host-response technologies, today announces that it will host a webinar entitled “Differentiating...

MeMed to host integrated symposium, oral presentation and poster spotlighting MeMed BV at the 32nd European Congress of Clinical Microbiology and Infectious Diseases Conference Haifa, Israel;...

Maimonides Medical Center Adopts Revolutionary Technology That Quickly Distinguishes Bacterial and Viral Infections Maimonides is the first hospital in New York to officially adopt the FDA-approved...

Fierce Medtech names MeMed as one of its ‘Fierce 15’ medical technology companies Haifa, Israel; Boston, MA – March 7, 2022 – MeMed today announced that it has been named by Fierce Medtech as one of...

MeMed raises $93M to accelerate commercialization of its host immune-response product portfolio MeMed BV® test recently cleared for use by US FDA to aid in distinguishing between bacterial and viral...

MeMed raises $93M to accelerate commercialization of its host immune-response product portfolio MeMed BV® test recently cleared for use by US FDA to aid in distinguishing between bacterial and viral...

MeMed raises $93M to accelerate commercialization of its host immune-response product portfolio MeMed BV® test recently cleared for use by US FDA to aid in distinguishing between bacterial and viral...